Filippo L Gurgoglione

Nov 28, 2024 | radcliffecardiology.com | Harriette Van Spall |Steven Nissen |Marc P. Bonaca |Filippo L Gurgoglione

AHA Conference 2024 - Safety and efficacy outcomes of zerlasiran (Silence Therapeutics) in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events (ASCVD). Dr Steven Nissen (Cleveland Clinic, US) joins us onsite at AHA Conference to discuss the findings from ALPACAR (NCT05537571).